FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 766 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 什么是癌症的肿瘤标志物检测？您需要需要知道的 8 件事 June 24, 2021 The new home for your research tools April 11, 2022 The Nobel Prize in Chemistry 2020 was Awarded “for the Development... October 12, 2020 Your questions on our research strategy March 29, 2022 Load more HOT NEWS This Program Provides Free Mammograms And Breast Cancer Treatment Services To... Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based...
